Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer.

[1]  Joe Y. Chang,et al.  Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer , 2018, JAMA network open.

[2]  R. Mohan,et al.  Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  Deric M. Park,et al.  Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy , 2018, Journal of Immunotherapy for Cancer.

[4]  C. Simone,et al.  Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer. , 2018, Lung cancer.

[5]  J. Welsh,et al.  Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  Steven H. Lin,et al.  A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. , 2018, Critical reviews in oncology/hematology.

[7]  C. Simone,et al.  Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. , 2017, Lung cancer.

[8]  A. Warth,et al.  Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  D. Gomez,et al.  Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy. , 2017, International journal of radiation oncology, biology, physics.

[10]  Joe Y. Chang,et al.  7‐year follow‐up after stereotactic ablative radiotherapy for patients with stage I non–small cell lung cancer: Results of a phase 2 clinical trial , 2017, Cancer.

[11]  S. Demaria,et al.  Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers , 2017, Clinical Cancer Research.

[12]  C. N. Coleman,et al.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.

[13]  N. Wulffraat,et al.  Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment. , 2017, Vaccine.

[14]  Joe Y. Chang,et al.  Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients. , 2017, The Annals of thoracic surgery.

[15]  P. Xia,et al.  A Histologic Basis for the Efficacy of SBRT to the lung , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  Joe Y. Chang,et al.  Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? , 2016, Nature Reviews Clinical Oncology.

[17]  Joe Y. Chang,et al.  Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. , 2016, International journal of radiation oncology, biology, physics.

[18]  Joe Y. Chang,et al.  Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. , 2016, Cancer journal.

[19]  B. Alexander,et al.  Steroid and anticonvulsant prophylaxis for stereotactic radiosurgery: Large variation in physician recommendations. , 2016, Practical radiation oncology.

[20]  Jan Nyman,et al.  SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  V. Verma.  Stereotactic Radiotherapy Versus Surgery for Early-Stage Operable Lung Cancer: More Questions Than Answers. , 2015, The Journal of the National Comprehensive Cancer Network.

[22]  Peter Balter,et al.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. , 2015, The Lancet. Oncology.

[23]  Joe Y. Chang,et al.  Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Joe Y. Chang,et al.  Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  Joe Y. Chang,et al.  Clinical Investigation : Thoracic Cancer Stereotactic Ablative Radiation Therapy for Centrally Located Early Stage or Isolated Parenchymal Recurrences of Non-Small Cell Lung Cancer : How to Fly in a “ No Fly Zone ” , 2022 .

[26]  Aaron D Ward,et al.  Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. , 2014, Medical physics.

[27]  Suresh Senan,et al.  High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  A. Ward,et al.  Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: A quantitative analysis of CT density changes , 2013, Acta oncologica.

[29]  M. Brock,et al.  Treatment-related Lymphopenia in Patients With Stage III Non-Small-Cell Lung Cancer , 2013, Cancer investigation.

[30]  Peter Balter,et al.  Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer , 2012, Radiation oncology.

[31]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[32]  Aaron Ward,et al.  Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  M. Binder,et al.  Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy , 2011, Medical oncology.

[34]  A. Gounni,et al.  The Molecular Mechanisms of Glucocorticoids-Mediated Neutrophil Survival , 2011, Current drug targets.

[35]  Andrea Bezjak,et al.  Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.

[36]  P. Lambin,et al.  Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  B. Neyns,et al.  Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Belka,et al.  Impact of localized radiotherapy on blood immune cells counts and function in humans. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  M. Borenstein,et al.  The effects of corticosteroids on lymphocyte recirculation in humans: analysis of the mechanism of impaired lymphocyte migration to lymph node following methylprednisolone administration. , 1995, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[40]  A. Fauci,et al.  Glucocorticosteroid therapy: mechanisms of action and clinical considerations. , 1976, Annals of internal medicine.